Loading stock data…
IRMD
$96.42+2.03 (+2.15%)
After Hours$96.42+0.00 (+0.00%)· Last close Jun 9
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
IRADIMED CORPORATION in the Healthcare sector is trading at $96.42 with a market capitalization of $1.2B. Wall Street consensus targets $118.00 (2 analysts), implying a +22.4% move over the next 12 months. The stock is currently 11% below its 52-week high of $107.90, remaining 8.6% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +22.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$96.42
Potential Downside
22%
Whystock Fair Value$75.18
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$118.00+22.4%
Range$116.00 – $120.00
Fundamentals
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.16B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
49.79
Beta
Defensive asset. Lower volatility than the S&P 500.
0.91
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.08%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.97%
Volume
Today's trading volume
153,908
Recent News
Assessing IRADIMED (IRMD) Valuation After Strong Multi Year Returns And A Premium P/E Multiple
Recent performance snapshot for IRADIMED (IRMD) IRADIMED (IRMD) has drawn investor attention after a period where the stock is up about 7% over the past month but down roughly 9% in the past 3 months, with a 1-year total return above 50%. See our latest analysis for IRADIMED. At a share price of $91.12, IRADIMED’s recent 1 day share price gain of 1.40% sits against a 7 day share price return that is slightly lower. Its 1 year total shareholder return of 52.01% and 5 year total shareholder...
IRADIMED's CEO Is Selling Steadily — The Plan, Not the Stock, Is Driving It
This medical device maker, known for MRI-compatible equipment, reported a notable insider sale amid strong one-year stock performance.
Iradimed Corp (IRMD): 3 Things That Stood Out From Q1 Report
Iradimed Corp (NASDAQ:IRMD) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. The stock has returned nearly 80% over the past year, and analysts see more upside potential in it. Iradimed reported its Q1 2026 results on May 1, and the results marked a strong start […]
Iradimed’s CEO and Founder Sold 7,500 Company Shares. What Does That Mean for Investors?
This medical device specialist, known for MRI-compatible equipment, reported a notable insider sale amid strong one-year share gains.
Reaffirmed Outlook And Dividend: What Does IRMD’s Confidence Signal About Its MRI Pump Moat?
In the past quarter ended March 31, 2026, IRADIMED CORPORATION reported first-quarter sales of US$21.98 million and net income of US$5.82 million, raised earnings per share versus a year earlier, reaffirmed its 2026 revenue and earnings outlook, and declared a regular US$0.20 quarterly dividend. The combination of year-over-year profit growth, maintained full-year guidance, and continued dividend payments highlights management’s confidence in the durability of IRADIMED’s MRI-compatible...